Brokerages predict that UroGen Pharma Ltd. (NASDAQ:URGN) will post $15.90 million in sales for the current quarter, Zacks reports. Three analysts have made estimates for UroGen Pharma’s earnings. The lowest sales estimate is $15.70 million and the highest is $16.00 million. UroGen Pharma posted sales of $3.46 million during the same quarter last year, which suggests a positive year over year growth rate of 359.5%. The company is expected to announce its next earnings report on Monday, November 8th.
On average, analysts expect that UroGen Pharma will report full year sales of $55.57 million for the current year, with estimates ranging from $54.10 million to $57.10 million. For the next financial year, analysts forecast that the firm will report sales of $127.43 million, with estimates ranging from $114.50 million to $135.80 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that cover UroGen Pharma.
UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Wednesday, August 4th. The company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($1.10) by ($0.07). The firm had revenue of $13.03 million for the quarter, compared to the consensus estimate of $13.00 million. UroGen Pharma had a negative net margin of 349.05% and a negative return on equity of 127.56%.
Hedge funds have recently bought and sold shares of the company. BNP Paribas Arbitrage SA increased its holdings in UroGen Pharma by 17.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 4,439 shares of the company’s stock worth $86,000 after acquiring an additional 657 shares in the last quarter. Public Employees Retirement System of Ohio boosted its holdings in UroGen Pharma by 21.1% in the 1st quarter. Public Employees Retirement System of Ohio now owns 6,900 shares of the company’s stock worth $134,000 after buying an additional 1,200 shares during the period. Algert Global LLC purchased a new stake in UroGen Pharma in the 1st quarter worth $227,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of UroGen Pharma during the second quarter worth about $239,000. Finally, Wells Fargo & Company MN grew its position in shares of UroGen Pharma by 368.3% during the second quarter. Wells Fargo & Company MN now owns 19,916 shares of the company’s stock worth $304,000 after purchasing an additional 15,663 shares in the last quarter.
UroGen Pharma stock traded up $0.29 during mid-day trading on Friday, reaching $15.43. 549 shares of the stock traded hands, compared to its average volume of 160,216. The stock has a market capitalization of $322.49 million, a PE ratio of -3.01 and a beta of 1.22. The business’s 50-day moving average is $15.73 and its 200-day moving average is $17.39. UroGen Pharma has a 12-month low of $14.19 and a 12-month high of $28.20.
UroGen Pharma Company Profile
UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. It has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs.
See Also: What is a growth and income fund?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.